Prosfora Technologies Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Prosfora Technologies Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $838.9K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Prosfora Technologies Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $838.9K Trade | TransData Nexus

Prosfora Technologies Private Limited

Indian Pharmaceutical Exporter · Analgesics & Antipyretics Specialist · $838.9K Total Trade · DGFT Verified

Prosfora Technologies Private Limited is an Indian pharmaceutical exporter with a total trade value of $838.9K across 2 products in 2 therapeutic categories. Based on 30 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Meloxicam ($538.9K), Clarithromycin ($300.0K), .

Prosfora Technologies Private Limited — Export Portfolio & Destination Treemap

Prosfora Technologies Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Prosfora Technologies Private Limited? — Company Overview & Market Position

Prosfora Technologies Private Limited is a privately held pharmaceutical company established on March 30, 2015, in Navi Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U74999MH2015PTC263227. Its authorized and paid-up capital stands at ₹0.19 million (₹190,000). As of April 8, 2024, Prosfora employed 57 professionals. The company's registered office is located at Aster, Flat-402, Plot No-10, Sector-06, Kharghar, Navi Mumbai, Maharashtra, 410210. Prosfora specializes in pharmaceutical contract research and development (R&D), focusing on both drug products and drug substances. The company has developed product technologies that have been out-licensed in over 50 countries, including the European Union, the United States, Canada, Australia, New Zealand, South Africa, Brazil, Mexico, and various Middle Eastern and North African countries.

What Does Prosfora Technologies Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Meloxicam$538.9K 2Clarithromycin

Product Portfolio — Top 2 by Export Value

Prosfora Technologies Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Meloxicam	Analgesics & Antipyretics	$538.9K	24	0.3%	14
2	Clarithromycin	Antibiotics	$300.0K	6	0.3%	15

Prosfora Technologies Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $838.9K. The top category is Analgesics & Antipyretics (64.2% of portfolio), followed by Antibiotics (35.8%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Prosfora Technologies Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Prosfora Technologies Private Limited operates manufacturing facilities in Navi Mumbai, Maharashtra. While specific details regarding plant capacities and specializations are not publicly disclosed, the company is known for its expertise in pharmaceutical contract R&D, encompassing both drug products and drug substances. Prosfora has assisted numerous pharmaceutical manufacturing sites, including those producing Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs), and clinical centers, in obtaining regulatory accreditations from major global agencies.

3Key Leadership

The leadership team at Prosfora Technologies Private Limited comprises:

Amit Rajan: Director since March 30, 2015.

Ruchi Amit Rajan: Director since March 30, 2015.

Specific roles such as Chief Executive Officer (CEO) and Chief Financial Officer (CFO) are not publicly disclosed.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Prosfora Technologies Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Prosfora Technologies Private Limited has a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and New Zealand. The company has filed 15 Abbreviated New Drug Applications (ANDAs) in the U.S. through end customers. Additionally, Prosfora has filed over 150 dossiers in the European Union, United Kingdom, Australia, New Zealand, Canada, and South Africa, with many under review. These filings indicate Prosfora's commitment to meeting the stringent regulatory requirements of these markets.

2Emerging Markets

Prosfora Technologies Private Limited has expanded its reach into emerging markets, including Africa, Latin America, and Southeast Asia. The company's product technologies have been out-licensed in over 50 countries, encompassing regions such as Africa, Latin America, and Southeast Asia. This strategic expansion enhances Prosfora's global footprint and access to diverse markets.

3Geographic Strategy

Prosfora Technologies Private Limited demonstrates a diversified geographic strategy by establishing a presence in both regulated and emerging markets. The company's significant export value of $839,000 USD across 30 shipments, primarily in the analgesics and antibiotics therapeutic categories, reflects a balanced approach to market penetration. This diversification mitigates concentration risk and positions Prosfora to leverage growth opportunities across various regions.

Prosfora Technologies Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Prosfora Technologies Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's involvement in the U.S. market, as evidenced by the filing of 15 ANDAs through end customers, suggests compliance with FDA regulations.

2WHO & EU GMP

Prosfora Technologies Private Limited has developed product technologies that have been out-licensed in over 50 countries, including those requiring compliance with World Health Organization (WHO) Good Manufacturing Practices (GMP) and European Union (EU) GMP standards. This indicates that Prosfora's manufacturing processes align with international quality standards, facilitating access to these markets.

3CDSCO & Indian Regulatory

Specific details regarding Prosfora Technologies Private Limited's manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), approvals from state drug controllers, and export No Objection Certificates (NOCs) are not publicly disclosed. However, the company's active participation in global markets and its role in assisting pharmaceutical manufacturing sites in obtaining regulatory accreditations suggest adherence to Indian regulatory requirements.

Prosfora Technologies Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Prosfora Technologies Private Limited operates in the competitive pharmaceutical contract research and development (R&D) sector. While specific competitors are not identified in the available data, the company's focus on both drug products and drug substances, along with its global licensing agreements, positions it as a significant player in the industry. The company's export value of $839,000 USD across 30 shipments, primarily in the analgesics and antibiotics therapeutic categories, reflects its competitive presence in these segments.

2Key Differentiators

Prosfora Technologies Private Limited's key differentiators include its expertise in pharmaceutical contract R&D, encompassing both drug products and drug substances. The company's product technologies have been out-licensed in over 50 countries, including the European Union, the United States, Canada, Australia, New Zealand, South Africa, Brazil, Mexico, and various Middle Eastern and North African countries. This extensive licensing portfolio demonstrates Prosfora's capability to meet diverse regulatory requirements and market needs.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Prosfora Technologies Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Prosfora Technologies Private Limited has a track record of assisting numerous pharmaceutical manufacturing sites, including those producing Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs), and clinical centers, in obtaining regulatory accreditations from major global agencies. This involvement suggests a reliable and consistent approach to supplier relationships, contributing to the company's reputation in the pharmaceutical industry.

2Certifications to Verify

Importers should verify the following certifications when considering Prosfora Technologies Private Limited as a supplier:

FDA Facility Registration: Confirm registration status through the FDA's official database.

WHO-GMP Certification: Verify compliance with WHO Good Manufacturing Practices by reviewing the company's certification documents.

EU GMP Certification: Ensure adherence to European Union Good Manufacturing Practices by examining the company's EU GMP certificates.

Frequently Asked Questions — Prosfora Technologies Private Limited

How many pharmaceutical products does Prosfora Technologies Private Limited export from India?

Prosfora Technologies Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Meloxicam ($538.9K), Clarithromycin ($300.0K). Total export value is $838.9K.

What is Prosfora Technologies Private Limited's total pharmaceutical export value?

Prosfora Technologies Private Limited's total pharmaceutical export value is $838.9K, based on 30 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Prosfora Technologies Private Limited cover?

Prosfora Technologies Private Limited exports across 2 therapeutic categories. The largest are Analgesics & Antipyretics (64.2%, 1 products), Antibiotics (35.8%, 1 products).

Get Full Prosfora Technologies Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.